Uccc-Hem-21-01- A Pilot Study To Assess The Immunological Response Of Covid-19 Vaccine Administered To Patients Receiving Rituximab And Other B Cell Depleting Therapies
Posted Date: May 20, 2021
- Investigator: Tahir Latif
- Specialties: Cancer, Oncology
- Type of Study: Observational/Survey
The goal of this study is to determine the immediate immunological response by measuring antibodies against SARS-CoV-2 spike protein at baseline, 4 and 8 weeks after SARS-CoV-2 vaccine administration in patients who are on active therapy with CD-20 with or without chemotherapy
Criteria:
Patients Must Be Over 18, Willing To And Who Will Be Receiving The Covid-19 Vaccinations, Cd-20 Therapy Group Includes Hematological Malignancy, Autoimmune Or Rheumatological Diagnosis Requiring Current Active Therapy With Cd-20 Antibodies With Or Without Chemotherapy, Or Whose Last Dose Of Cd-20 Therapy Is Within 6 Months Of Planned Covid-19 Vaccine Administration. Control Group Are Patients With Any Malignancy Or Rheumatological Diagnosis Or Autoimmune Diagnosis That Have Never Received C20 Antibodies.
Keywords:
Covid-19, Vaccine, Hematology
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com